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ABSTRACT 
The prevalence of low bone mineral density (BMD) is increased in individuals with 
chronic obstructive pulmonary disease (COPD) independent of traditional osteoporosis 
risk factors. COPD-specific guidelines for BMD assessment do not exist and general 
guidelines for osteoporosis screening do not recognize COPD as a risk factor for 
fracture. Nonetheless, osteoporotic fractures are of major public health importance 
given the negative impact of fractures on morbidity and mortality in COPD patients. 
Furthermore, increased bone turnover independently contributes to fracture risk yet 
cannot be determined by cross-sectional dual x-ray absorptiometry (DXA) assessment 
alone. We established a longitudinal cohort of male and female smokers with and 
without smoking-related lung disease (i.e. emphysema or airflow obstruction) to 
determine factors related to accelerated BMD loss in smokers. We obtained baseline 
and 2-year measurements of pulmonary function, BMD, radiographic emphysema, and 
demographic and clinical characteristics. We assayed baseline blood samples for 
markers of bone metabolism, vitamin D, matrix metalloproteinases (MMP) and their 
inhibitors, interleukin-6, and tumor necrosis factor alpha.   Of those with lung disease, 
48.6% had evidence of osteopenia or osteoporosis at baseline compared to 29.4% 
without lung disease (p=0.01). The incidence of accelerated hip or lumbar spine BMD 
loss was 33.8% in subjects with lung disease versus 19.6% in those participants without 
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lung disease (p=0.01). Both type I collagen C telopeptide (CTx), a marker of bone 
resorption, and radiographic emphysema were independent predictors of accelerated 
BMD loss (OR 5.5 [2.1,14.4] for moderate/severe emphysema; OR 2.9 [1.3,6.4] for 
highest tertile CTx) when adjusted for age, gender, steroid use, and current smoking 
status. Tissue inhibitor of matrix metalloproteinase (TIMP) 4 was independently 
associated with BMD decline at the hip (p=0.04) and higher in subjects with emphysema 
progression (p=0.03). TIMP1 and MMP7 levels were also higher in subjects with 
emphysema progression. These findings suggest that accessible and easily measured 
biomarkers may be used to guide early and serial DXA BMD assessments in a subset 
of smokers at risk for accelerated BMD decline. TIMP4 and MMPs may further be 
involved in the regulation of lung and bone matrix degradation in individuals with 
emphysema-related BMD decline. 
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1.0 INTRODUCTION 
Osteoporotic fractures contribute to increased morbidity and mortality in patients with 
chronic obstructive pulmonary disease (COPD) (1-3). Whereas osteoporosis risk factors 
including decreased physical activity levels, increased steroid use, and frailty are 
common in severe obstructive lung disease, numerous studies have demonstrated an 
increased prevalence of low bone mineral density (BMD) even in those individuals with 
mild airflow obstruction (4-9). Criteria for BMD assessment in COPD patients remain 
undefined while general osteoporosis screening guidelines fail to recognize chronic lung 
disease as a major risk factor for fracture (10-12). As such, clinicians caring for patients 
with COPD may miss a substantial proportion of patients with significant bone loss who 
are at high risk for debilitating fractures. Subsets of patients, notably men, are at 
particular risk of missed diagnosis given low general screening rates in these 
populations (2). 
 
Dual x-ray absorptiometry (DXA) assessment of BMD in all patients with COPD is not 
common clinical practice. BMD assessments limited to those patients with the most 
severe lung disease may exclude patients with significant bone loss whereas universal 
screening of all COPD patients is probably not cost-effective.  Further, a single cross-
sectional BMD assessment provides no information regarding the rate of BMD loss, a 
separate and important risk factor for osteoporotic fracture (13, 14). Thus, a need exists 
for an easily measureable biomarker associated with accelerated BMD decline that may 
be used to target screening in COPD patients at highest fracture risk. Early detection of 
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COPD patients with low BMD, or accelerated BMD loss, with targeted DXA BMD 
assessments will lead to earlier treatment strategies for fracture prevention. 
  
Large cohort studies designed to study the influence of genetic variation or patterns of 
inflammation on disease expression have advanced the field of clinical phenotyping in 
COPD (15, 16). However, the study of BMD loss in these cohorts is challenged by the 
fact that, without systematic assessments of BMD, osteoporosis remains silent until 
fracture occurs, thus impacting the accuracy of a patient-reported osteoporosis 
diagnosis. We have established a cohort of current and former smokers with and 
without smoking-related lung disease, defined as either radiographic emphysema or 
airflow obstruction (9). We have followed this cohort for 2 years with serial assessments 
of clinical and demographic data, pulmonary function, radiographic emphysema, and 
BMD. We have also measured baseline circulating serum biomarker levels. This cohort 
provides the opportunity to study the natural history of BMD loss in smokers with and 
without lung disease and to examine factors associated with BMD loss. We hypothesize 
that accelerated BMD loss is prevalent in smokers with lung disease and that clinical, 
radiographic, and molecular biomarkers can be used to identify smokers at risk for rapid 
BMD decline. 
 
2.0 METHODS 
2.1 Subject Selection 
The study population consisted of 240 male and female subjects participating in the 
COPD Specialized Center for Clinically Oriented Research (SCCOR) at the University 
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of Pittsburgh. Subjects were current or former smokers ages 40-79 with a minimum of 
10 pack-years tobacco history at enrollment. One hundred thirty nine subjects had 
smoking-related lung disease, defined as either visual emphysema on CT scan or 
airflow obstruction [forced expiratory volume in 1 second to forced vital capacity ratio 
(FEV1/FVC) less than 0.70]. The remaining 101 participants had no evidence of visual 
emphysema or airflow obstruction. Exclusion criteria included chronic daily prednisone 
use, clinical or radiographic evidence of another significant pulmonary diagnosis (e.g. 
interstitial lung disease), history of lung cancer or a new, suspicious nodule on CT scan, 
obesity with a BMI > 34, active treatment with bisphosphonate therapy, calcitonin, 
denosumab, raloxifene, or parathyroid hormone replacement, or active treatment with 
hormone replacement therapy. Each subject completed a chest CT scan, pre and post-
bronchodilator spirometry and plethysmography, measurement of lung diffusion 
capacity, demographic and medical history questionnaires, and DXA measurements of 
hip and lumbar spine BMD at baseline and 2 years. Physical activity levels were 
quantified using a validated, five-point activity questionnaire that addressed both on-the-
job and leisure activity levels (17). Symptom scores were assessed with the Saint 
George’s Respiratory Questionnaire (18). Blood specimens were collected at each 
study visit. The study protocol was approved by the University of Pittsburgh Institutional 
Review Board and written informed consent was obtained for each subject. 
2.2 Dual X-Ray Absorptiometry 
BMD at the hip and lumbar spine were determined using a Hologic 4500A Discovery 
bone densitometer.  BMD is reported as an absolute value (gm/cm2) and a T score, the 
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number of standard deviations from a young, gender and ethnic specific reference 
mean, using the NHANES III database reference population for hip BMD measurements 
(19) and the Hologic database reference population for spine BMD measurements.  T 
scores were used to classify subjects as having normal BMD (T score > -1.0), 
osteopenia (-2.5 < T score < -1.0), or osteoporosis (T score < -2.5). 
2.3 CT Scans 
Noncontrast CT examinations were performed with a General Electric (GE) LightSpeed 
VCT (64-detector) scanner.  A single chest radiologist, blinded to subject identities and 
other characteristics, interpreted the CT images using a 6-point semi-quantitative visual 
scoring system to define emphysema severity (0=none, 1=trace, 2=mild, 3=moderate, 
4=severe, 5=very severe) which corresponded to 0%, <10%, 10-25%, 26-50%, 51-75%, 
and > 75% visual emphysema.  Our group has validated this methodology in a previous 
publication (20). The percentage of low attenuation areas (LAA%) was defined as the 
fraction of voxels less than -950 HU as a percent of total voxels per identification of lung 
regions similar to the traditional density mask (21). Radiographic progression was 
defined as greater than a 0.5% annual increase in LAA. 
2.4 Biomarker Measurements 
Baseline blood samples were analyzed for the following biomarkers. Type I collagen c-
telopeptide (CTx), a marker of bone resorption (14, 22), receptor activator of nuclear 
factor kappa beta ligand (RANKL) and osteoprotegerin (OPG) were measured by a 
commercially available electrochemiluminescence-based immunoassay using Roche 
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Elecsys2010 (Roche Diagnostics). Amino-terminal propeptide of type I procollagen 
(P1NP), a marker of bone formation (14, 22), was measured with a commercial 
radioimmunoassay kit from Immunodiagnostic Systems Inc. Matrix metalloproteinase 
(MMP) 1, MMP7, tissue inhibitor of matrix metalloproteinase (TIMP) 1, TIMP2, and 
TIMP4 were measured using Performance Assay MMP and TIMP multi-plex kits (R and 
D Systems) on a Luminex system. Interleukin (IL) 6 , TNF-alpha, and vitamin D were 
measured by enzyme-linked immunoabsorbant assay (ELISA) in duplicate. All assays 
and kits were used according to manufacturers’ instructions. All samples were above 
the detection level for each measured biomarker.  
 
2.5 Statistical Analysis 
Annual percent change in total hip and lumbar spine BMD was calculated for each 
subject. A Monte Carlo simulation with 10,000 iterations was performed separately on 
both male and female subjects with no evidence of emphysema or airflow obstruction to 
obtain separate, smoothed estimates of the distribution of annual BMD percent change 
at the hip and lumbar spine among both male and female cohort participants without 
smoking-related lung disease. A prior population-based study (23) showed that every 
one standard deviation below the mean annual BMD percent change at the femoral 
neck (corresponding to approximately the lower 16% of the population under normal 
distribution assumptions) was associated with 3.9 excess hip fractures per 100 persons. 
Given the non-normal distribution of BMD change in our longitudinal cohort, we thus 
chose a conservative 10th percentile cut-off to define accelerated BMD loss at the hip 
and lumbar spine. Definitions of accelerated BMD loss were then applied to both those 
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with and without smoking-related lung disease and cohort participants below the 10th 
percentile threshold at either the hip or lumbar spine were classified as having 
accelerated BMD loss. The entire tobacco-exposed cohort, regardless of lung disease 
status, was included in all analyses. The characteristics of subjects with and without 
accelerated BMD loss were compared using Student’s t-test for continuous variables 
and chi-square analysis for categorical variables. Wilcoxon rank-sum test was used for 
non-normally distributed variables. Univariable and multivariable logistic regression 
analyses were performed to assess factors related to accelerated BMD loss. 
Biomarkers were included in the models as both continuous and categorical (tertile) 
variables. Biomarker tertiles and median levels were determined using the entire 
tobacco-exposed cohort. Biomarkers that were not normally distributed were log-
transformed. Associations between biomarkers were assessed by Spearman 
correlation. Models were adjusted for age, gender, steroid use, and smoking status. The 
relationship between plasma biomarkers and absolute change in BMD at the total hip 
and lumbar spine were assessed with univariable and multivariable regression analyses 
adjusting for age, gender, smoking status, and steroid use. All statistical analyses were 
performed using SAS 9.2 and Stata 13.1. 
 
3.0 RESULTS 
3.1 Subject Characteristics 
The mean age of the cohort was 66.7 years with an equal distribution of men and 
women. Although cohort participants had a significant degree of tobacco use and 40% 
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continued to smoke, lung disease in the cohort was mild with only approximately 29% of 
the cohort having moderate or severe airflow obstruction (Table 1).  
As a result, both inhaled and oral steroid use was low. However, radiographic 
emphysema was present in almost half of the cohort participants with 57.9% of the 
cohort having evidence of either radiographic emphysema or airflow obstruction. 
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3.2 Prevalence of Low Bone Mineral Density and Accelerated Bone Mineral 
Density Loss  
The prevalence of low BMD was high with 60% of the entire cohort having low BMD on 
baseline DXA assessment (Table 1).  Osteopenia and osteoporosis were significantly 
more common in cohort participants with smoking-related lung disease compared to 
unaffected smokers (p=0.01, Figure 1). Notably, 65% of cohort participants with lung  
disease and osteopenia and 29% of those with lung disease and osteoporosis did not 
meet the established age criteria for osteoporosis screening (> 65 year of age in 
women, >70 years of age in men). Annual median percent loss in BMD at the hip was 
0.2% and 0.5% for males and females with lung disease respectively. Males without 
Figure 1:  Prevalence of normal bone mineral density, osteopenia, 
and osteoporosis in those with and without smoking-related lung 
disease (radiographic emphysema and/or airflow obstruction). P=0.01 
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lung disease had a 0.2% annual median percent increase in BMD at the hip while 
females without lung disease still had 0.7% median percent loss in hip BMD (Figure 2).  
Figure 2: Distribution of annual percent change in hip bone 
mineral density for males and females with and without lung disease
	  10	  
 Males and females with or without lung disease demonstrated slight increases in 
lumbar spine BMD over the 2-year study interval. Using the 10th percentile cut-off of the 
Monte Carlo simulated distribution of annual percent BMD change for cohort 
participants without smoking-related lung disease, accelerated BMD loss was defined 
as an annual percent BMD loss of greater than 1.9% at the hip or 1.2% at the lumbar 
spine for women and greater than .74% at the hip or 0.24% at the lumbar spine for men. 
Of those with smoking-related lung disease, 47 (33.8%) had evidence of accelerated 
BMD loss at either the hip or lumbar spine over the 2-year study period.  Again, the 
majority (68%) of those with lung disease and accelerated BMD loss did not meet age 
criteria for osteoporosis screening. In contrast, only 20 (19.6%) of unaffected smokers 
demonstrated rapid BMD decline at either the hip or lumbar spine (p=0.01). 
3.3 Factors Associated with Accelerated Bone Mineral Density Decline 
Age, gender distribution, BMI, steroid use, and current smoking status did not differ 
between those subjects with and without rapid BMD decline; although annual percent 
change in hip BMD did decrease with increasing age (p=0.013) and decreasing BMI 
(p=0.001). A greater proportion of subjects with accelerated BMD loss had evidence of 
either radiographic emphysema or airflow obstruction compared to those with stable 
BMD over time (70.1% vs. 52.6%, p=0.01, Table 2). This increased prevalence of rapid 
BMD loss appeared to be driven by the presence of emphysema rather than the 
severity of airflow obstruction. In fact, the odds of accelerated BMD loss were 2.1 times 
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Table 2: Characteristics of Subjects with and without Accelerated 
 Bone Mineral Density Loss 
No Accelerated Loss (-) 
n=173 
Accelerated Loss (+) 
n=67 
P-Value 
Age, mean (SD) 64.4 (0.4) 64.2 (0.8) 0.85 
Gender, male, n (%) 87 (50.3) 39 (58.2) 0.27 
BMI, mean (SD) 28.6 (0.3) 27.8 (0.5) 0.16 
Pack Years, mean (SD) 47.3 (1.9) 50.3 (2.9) 0.41 
Current Smoker, n (%) 74 (42.8) 28 (41.8) 0.89 
Emphysema or Obstruction, n (%) 91 (52.6) 47 (70.1) 0.01 
Emphysema Present, n (%) 74 (42.8) 41 (61.2) 0.01 
LAA%, median (IQR) 0.5 (0.8) 0.8 (3.1) 0.08 
FEV1 %, mean (SD) 86.5 (1.4) 81.7 (2.7) 0.18 
ICS Use, n (%) 16 (9.2) 11 (16.4) 0.11 
Oral Steroid Use, n (%) 10 (5.8) 5 (7.5) 0.62 
Activity Score, median (IQR) 3 (1) 2.5 (2) 0.46 
Symptom Score, median (IQR) 14.2 (19.5) 13.9 (25.7) 0.45 
Vitamin D ng/ml, median (IQR) 33.7 (25.9) 32.1 (32.2) 0.52 
CTx pg/ml, median (IQR) 248 (192) 322 (205) 0.01 
P1NP pg/ml, median (IQR) 28.5 (14.2) 28.2 (18.8) 0.66 
OPG pg/ml, median (IQR) 1092.6 (580.3) 1216.5 (631.7) 0.05 
RANKL pg/ml, median (IQR) 94.2 (113.1) 98.2 (116.2) 0.98 
TIMP1 pg/ml, median (IQR) 65490.3 (19518.4) 64189.7 (19383.8) 0.67 
TIMP2 pg/ml, median (IQR) 63679.9 (10436.5) 64360.3 (10304.7) 0.84 
TIMP4 pg/ml, median (IQR) 1193.6 (647.7) 1247.5 (753.6) 0.21 
MMP1 pg/ml, median (IQR) 1789.1 (1693.0) 2093.6 (1941.8) 0.24 
MMP7 pg/ml, median (IQR) 11278.15 (6736.2) 10683.5 (8813.4) 0.41 
IL6 pg/ml, median (IQR) 1.22 (1.39) 1.38 (1.15) 0.73 
TNF-alpha pg/ml, median (IQR) 1.89 (1.27) 1.94 (1.23) 0.62 
BMI=body mass index; FEV1=forced expiratory volume in 1 second; LAA=low attenuation areas; ICS=inhaled 
corticosteroids; CTx=type I collagen C-telopeptide; P1NP=amino terminal propeptide of type I procollagen; 
OPG=osteoprotegerin; RANKL=receptor activator of nuclear factor kappa beta ligand; TIMP=tissue inhibitor of matrix 
metalloproteinases; MMP=matrix metalloproteinase;  TNF=tumor necrosis factor 
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higher in subjects with any evidence of radiographic emphysema (p=0.01) and 5.2 times 
higher in subjects in whom emphysema was moderate or severe (p<0.001). These 
findings remained significant after adjustment for age, gender, current smoking status,  
and steroid use (Table 3). Whereas a trend for greater odds of accelerated BMD 
decline did exist in subjects with airflow obstruction (OR 1.7, p=0.06), this effect was lost 
after emphysema severity was included in the model.  
CTx levels were higher among those cohort participants with accelerated BMD decline 
(322 [205 IQR] vs. 248 [192 IQR], p=0.01, Table 2) whereas vitamin D levels and other 
circulating biomarker levels did not differ between groups.  
As shown previously (24), CTx levels were highly correlated with P1NP levels (r=0.61, 
p<0.0001). Participants with CTx levels above the median value had a 1.9 greater 
chance of having accelerated BMD loss (OR 1.9, p=0.03) and those with the highest 
tertile of CTx levels were 3 times more likely to have rapid BMD decline (OR 3.05, 
p=0.01).  The addition of age, gender, current smoking status, and steroid use to the 
model did not impact the significance of these findings. A multivariable model including 
emphysema severity and CTx tertile showed that both the severity of radiographic 
	  13	  
emphysema and circulating CTx levels are independent predictors of accelerated BMD 
loss (Figure 3) when adjusted for age, gender, steroid use, and smoking status. The 
presence of any radiographic emphysema or CTx values above the median level 
likewise predicted rapid BMD loss after accounting for other potential confounders 
(Table 4).  
Figure 3: Forest Plot showing predictors of accelerated bone mineral density loss in multivariable 
logistic regression analysis.
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3.4  Serum Biomarkers Associated with Bone Mineral Density Change 
TIMP4 levels were associated with a decrease in annual percent change in hip BMD in 
univariable regression analysis (p<0.001). This relationship remained significant after 
adjustment for age, gender, BMI and current smoking status. In fact, multivariable  
modeling showed that TIMP4 levels, age, gender, and BMI were all independently 
associated with BMD loss at the hip (R2=17.8, p<0.001, Table 5).   
Baseline TIMP4 levels, as well as TIMP1 and MMP7 levels, were likewise higher in 
subjects with radiographic progression of emphysema (n=27, 11.3%, Table 6) 
	  15	  
compared to those with stable lung disease over the 2-year study interval.  Annual 
percent change in spine BMD was small in the overall cohort and was not associated 
with circulating biomarker levels or other osteoporosis risk factors (data not shown). 
 
4.0 DISCUSSION 
4.1 Summary of Findings and Review of the Literature 
We have shown that the prevalence of osteopenia and osteoporosis is increased in 
smokers with smoking-related lung disease (i.e. emphysema or airflow obstruction) 
when compared to smokers with similar demographic and clinical characteristics. The 
incidence of accelerated BMD loss is high in this group with the positive correlation 
between CTx, a marker of bone resorption, and P1NP, a marker of bone formation, 
suggesting that BMD decline in smokers is due to a high turnover state. The majority of 
subjects with osteopenia or osteoporosis were below the recommended screening age 
for osteoporosis (10, 11) and traditional risk factors, including age, gender, and steroid 
use, did not differentiate those subjects with accelerated BMD loss from those without. 
Two easily accessible biomarkers, radiographic emphysema and serum CTx levels, 
independently predicted accelerated decline in BMD over a short follow-up interval.  
Further, a circulating inhibitor of matrix metalloproteinases, TIMP4, was independently 
associated with BMD loss at the hip after adjustment for other factors commonly 
attributed to BMD decline. 
 
Osteoporosis and osteoporotic fractures are a significant public health problem in 
individuals with smoking-related lung disease. Individuals with COPD who sustain hip 
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fractures have 60-70% higher rates of mortality compared to individuals with hip 
fractures who do not have evidence of lung disease (1). Further, in those patients with 
COPD, hip fracture increases 1-year mortality up to 3 to 5 times that of COPD patients 
without fracture (1). Osteoporotic vertebral fractures can lead to reductions in forced 
vital capacity and FEV1, further impairing lung function in individuals who already have 
low pulmonary reserve (3). Yet, osteoporosis screening rates remain low in persons 
with COPD, particularly in subgroups, such as men, where general osteoporosis 
screening guidelines have not reached a uniform consensus. For example, a study of 
the Veterans Affairs electronic database revealed a high fracture rate (3.99 and 1.31 per 
1000 person years for hip and wrist fractures respectively) with only rare BMD 
assessments (4.4%) and osteoporosis treatment (2.8%) in male veterans with COPD 
(2). Findings from our study further highlight the complexities of osteoporosis screening 
in smoking-related lung disease with only 35.1% of those with low BMD and 32.0% with 
accelerated BMD loss meeting screening criteria for BMD assessment.  
 
The finding that both radiographic emphysema and serum CTx levels independently 
predict rapid BMD decline coupled with literature linking emphysema with cross-
sectional assessments of BMD (9, 25) offers a potential means of identifying patients 
with smoking-related lung disease who should undergo early and serial DXA BMD 
assessment. Studies have shown that the rate of bone loss may be as important as 
absolute bone mineral density when determining fracture risk (13, 14). Cross-sectional 
assessments of BMD, even if performed at an earlier age than guidelines currently 
advise, provide no information regarding rate of BMD decline. As evidence in support of 
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lung cancer CT screening (26) and experimental options for endoscopic lung volume 
reduction increase (27, 28), the frequency of routine chest CT scans in the management 
of patients with COPD will continue to rise. Meanwhile, commercial assays for CTx are 
readily accessible and available in most clinical laboratories.  A strategy incorporating 
these two biomarkers to direct targeted osteoporosis screening will likely be more cost-
effective than universal screening in all patients with COPD. The age at which screening 
should commence remains unclear, although our findings would suggest that initial 
BMD assessment before the age of 65 is warranted. The impact of age on prevalence 
of low BMD and BMD decline should be systematically studied in a COPD cohort with a 
more diverse distribution of age and disease severity to establish age criteria for 
osteoporosis screening in COPD patients. 
 
The independent association between radiographic emphysema and low BMD that has 
been demonstrated in numerous studies (9, 25) suggests a common mechanism linking 
lung and bone matrix destruction. Our findings would suggest that MMPs and MMP 
inhibitors are important contributors to these synchronous processes. TIMP4, an 
inhibitor of MMPs, was the only circulating biomarker associated with change in BMD at 
the hip over the 2-year study interval. TIMP4, as well as TIMP1 and MMP7, was also 
higher in those subjects demonstrating radiographic emphysema progression over 2 
years. MMPs play an important role in tissue remodeling in both emphysema and 
osteoporosis (29-32). TIMP4 levels may increase in response to lung or bone matrix 
destruction by MMPs and other pro-inflammatory cytokines. We did not find a significant 
association between serum MMP levels and BMD change. However, the follow-up 
	  18	  
interval was short, a small number of MMPs were assayed, and only baseline MMP 
levels were assessed. Further investigation into the role MMPs and their inhibitors play 
in COPD-related BMD loss is warranted given their potential as both diagnostic and 
therapeutic biomarkers. 
 
4.2 Strengths and Limitations 
The strength of our cohort lies in the availability of longitudinal, gold standard 
assessments of BMD coupled to well-characterized clinical data in smokers with few 
competing osteoporosis risk factors. Most epidemiologic cohorts to date either provide 
systematic BMD or fracture assessments with little information regarding both lung 
function and radiographic emphysema (4, 5)  or detailed pulmonary function and CT 
data without gold-standard assessments of BMD (33). No published studies to date 
have assessed longitudinal BMD loss in individuals with smoking-related lung disease. 
Despite the mild severity of underlying lung disease, a significant proportion of our 
cohort experienced substantial BMD loss in a relatively short time period. We would 
expect to see even greater BMD decline over several years, given that BMD loss likely 
does not follow a linear trajectory, particularly in individuals with COPD where systemic 
inflammation may wax and wane with lung disease activity (34-37).  
 
The absence of longitudinal cohorts examining BMD loss specifically in smokers creates 
a challenge when defining accelerated BMD loss in our cohort. Population based 
studies of healthy individuals have used absolute thresholds (>0.4% BMD loss per year 
in post-menopausal females, no change in men)  (38) or standard deviations from the 
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mean (one standard deviation below the mean associated with an excess of 3.9 hip 
fractures per 100 persons) (23) to define accelerated BMD loss or to determine clinically 
meaningful BMD change respectively. Thresholds defined by these studies may not be 
appropriate for our cohort, all of whom have had a significant smoking history. However, 
the availability of complete pulmonary function and radiographic data in our cohort 
participants provided us the opportunity to define a smoking control group that has a 
common risk factor (smoking) but has not developed lung disease. Because BMD data 
from our cohort was not normally distributed, we extrapolated the findings of Berry et al. 
(23) and chose the 10th percentile, well below the 16th percentile that would correspond 
to one standard deviation below the mean found significant in their study, below which 
accelerated BMD loss was defined. Thresholds to define accelerated BMD loss 
established by this methodology were greater than those used in a prior study to define 
accelerated BMD loss in a healthy population (38). 
 
Finally, the paucity of longitudinal COPD cohorts with systematic measurements of 
BMD limits our ability to validate our results at present. However, validation of our 
findings in a separate, more clinically relevant cohort of COPD patients with more 
severe lung disease will be necessary, and is currently planned, to confirm our findings 
and identify any additional factors associated with bone loss in those with more 
extensive disease. 
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4.3 Public Health Significance 
COPD is the third leading cause of death in the United States (39). The increased 
prevalence of osteopenia and osteoporosis in individuals with COPD has a significant 
impact on both morbidity and mortality (1-3), yet screening guidelines fail to recognize 
COPD as a major risk factor to warrant early BMD assessment and monitoring (10, 11). 
Universal osteoporosis screening of all COPD patients at an earlier age than currently 
recommended by general osteoporosis screening guidelines is not cost-effective. As 
such, research addressing which subset of COPD patients should undergo early, and 
perhaps serial, BMD assessments is of great public health importance.  
 
5.0 CONCLUSION 
We have confirmed that low BMD is prevalent in smokers with emphysema or airflow 
obstruction and are the first to show that significant proportions of individuals with 
smoking-related lung disease have accelerated BMD decline. Low osteoporosis 
screening rates combined with detrimental outcomes following fracture in patients with 
COPD has given rise to a significant public health problem for many current and former 
smokers. The incorporation of biomarkers associated with accelerated BMD decline into 
osteoporosis screening algorithms may facilitate selection of individuals for early and 
serial BMD monitoring and ultimately alter clinical practice for our chronic lung disease 
patients.  
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